Etrasimod
Olorinab
Partners & Licensees
Olorinab (APD371)
Oliver Fetzer, Ph.D.
Dr. Fetzer serves as the Chief Executive Officer of Synthetic Genomics, Inc., a private synthetic biology company commercializing genomic technologies, since October 2014. Prior to Synthetic Genomics, Dr. Fetzer was President and Chief Executive Officer of Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, from April 2009 to October 2014. Prior to Cerulean Pharma, Dr. Fetzer served in a variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director. Dr. Fetzer served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and of Cerulean Pharma, Inc. from 2009 to 2014, and has served on the board of Tecan Group AG, a publicly traded provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, since 2011. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an M.B.A. from Carnegie Mellon University.
Arena Pharmaceuticals
© Copyright 2000-2019 Arena Pharmaceuticals, Inc.
All images are owned or licensed by Arena Pharmaceuticals and may not be downloaded or reproduced.
Terms and Conditions | Privacy Statement |
Social Media Community Guidelines
6154 Nancy Ridge Drive San Diego, CA 92121
100 Summer Street, Ste 1600, Boston, MA 02110
IR@arenapharm.com
Gotthardstrasse 3, 6300 Zug. Switzerland